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The role of magnetic resonance imaging in the
prediction of the neurodevelopmental outcome of
acute bilirubin encephalopathy in newborns
Aim: Magnetic resonance imaging (MRI) is widely used in the diagnosis of acute bilirubin
encephalopathy, but the relationship between MRI findings and neurodevelopmental outcome in
newborns with acute bilirubin encephalopathy remains unclear. The aim of this study was to
investigate the relationship between acute bilirubin encephalopathy, MRI findings, and
neurodevelopmental outcome.
Materials and Methods: The study included 13 infants with acute bilirubin encephalopathy. MRI was
performed at 11-30 days of age. Infants were evaluated using the Denver Developmental Screening
Test at 3 and 6 months of age.
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Results: Four of the 13 infants developed well. Five infants had abnormal MRI findings. Two of these
5 infants had good neurodevelopmental outcome. Nine of the 13 patients had poor developmental
outcomes.
Conclusion: In newborns with acute bilirubin encephalopathy, neither encephalopathy stage nor
MRI findings predicted neurodevelopmental outcome, as measured by the Denver Developmental
Screening Test.
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kernicterus

Manyetik rezonans görüntülemenin akut bilirübin ensefalopatili
yenidoğanların nörogelişimsel sonuçlarını tahmin etmedeki rolü
Amaç: Manyetik rezonans görüntüleme (MRG) akut bilirübin ensefalopati tanısında yaygın
kullanılan bir tanı yöntemidir. Ancak MRG bulgularıyla akut ensefalopatili yenidoğanların
nörogelişimsel sonuçları arasındaki ilişki halen net değildir. Bu çalışmanın amacı akut bilirübin
ensefalopatili yenidoğanların nörogelişimsel sonuçlarını önceden tahmin etmede MRG’nin rolünü
araştırmaktır.
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Yöntem ve Gereç: Akut bilirübin ensefalopatisi olan 13 yenidoğan çalışmaya alındı. MRG
yenidoğanların 11 ile 30. günleri arasında çekildi. Hastalar 3. ve 6. aylarında “Denver Developmental
Screening Test” ile nörogelişimsel olarak değerlendirildi.
Bulgular: Çalışmaya dahil edilen 13 yenidoğanın 4’ü nörogelişimsel olarak normal, 9’u da anormal
olarak bulundu. Toplam 5 hastada da normal olmayan MRG bulguları saptandı. Bu 5 hastanın 2’si
nörogelişimsel olarak normal olarak bulundu.
Sonuç: Akut ensefalopatili yenidoğanlarda MRG bulguları ve ensefalopatinin düzeyi “Denver
Developmental Screening Test” ile ölçülen nörogelişimsel sonuçları tahmin edememektedir.
Anahtar sözcükler: Akut bilirübin ensefalopatisi, hiperbilirübinemi, manyetik rezonans
görüntüleme, kernikterus

Introduction
Acute bilirubin encephalopathy (ABE) refers to the clinical findings caused by
bilirubin toxicity to the basal ganglia and various brainstem nuclei. The American
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Academy of Pediatrics recommends that this term be
used to describe the acute manifestations of bilirubin
toxicity seen during the first weeks after birth and that
the term kernicterus be reserved for the chronic and
permanent clinical sequelae of bilirubin toxicity (1).
Bilirubin toxicity remains a significant problem
despite recent advances in the care of infants with
jaundice. Early discharge policies and increased
breastfeeding have increased the risk of marked
hyperbilirubinemia and kernicterus (2). In recent
years there has been an increase in the number of
reported cases of kernicterus (3,4).
The pathological changes caused by the cytotoxic
effect of unconjugated bilirubin include discoloration
and destruction of affected neurons (3). The pallidum,
subthalamic nucleus, and hippocampus are the most
commonly affected areas, whereas the cerebral cortex,
white matter, midbrain, and brain stem are
unaffected. Other structures, such as the thalamus,
striatum, substantia nigra, cerebellar nuclei, inferior
olivary nuclei, and various cranial nerve nuclei may
also be involved (5). Recognition of the signs of ABE
is vital, as prompt treatment may be successful in
reversing the damage. Shapiro has emphasized that
the faster and more aggressive the treatment, the more
reversible and better the outcome (6).
Pathological changes in affected regions of the
brain can be detected as high signal intensity with
magnetic resonance imaging (MRI) in infants with
kernicterus (7,8). Although MRI is widely used in the
diagnosis of kernicterus, the relationship between
MRI findings and neurological outcome in newborns
with ABE remains unclear. The aim of the present
study was to investigate the relationship between ABE,
MRI findings, and neurodevelopmental outcome.
Patients and Methods
Newborns with severe jaundice that were admitted
to our institution’s neonatal intensive care unit were
enrolled in this prospective study. Recruitment
criteria included the presence of ABE, bilirubin levels
≥ 30 mg dL−1, and gestational age ≥ 37 weeks.
Newborns without ABE or those with major
congenital malformations or infections were excluded
from the study. Our institution’s ethics committee
approved the study protocol, and informed consent
was obtained from the parents of each infant.
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All infants were examined by a neonatologist at
admission. Clinical signs of ABE, including alteration
in consciousness, muscle tone, movement, and
brainstem function (lethargy, irritability, poor feeding,
abnormal crying, muscle tone abnormalities, arching,
opisthotonus, and seizures) were recorded. All
patients were classified according to previously
described ABE criteria: initial (phase I), moderate
(phase II), and severe (phase III) (9). All patients
underwent intensive phototherapy and 1 or more
exchange transfusions.
Laboratory studies included complete blood
count, direct Coombs test, reticulocyte count, Rh
compatibility, and serum electrolytes and glucose
levels. We were unable to test for glucose-6-phosphate
dehydrogenase deficiency due to technical issues.
Cranial MRI was performed between 11 and 30
days (mean 18 days) after the clinical onset of
encephalopathy. All patients were scanned using the
same 1.5 Tesla scanner (Picker International,
Cleveland, Ohio, USA) and all scans were evaluated
by the same radiologist.
Complete neurological examinations were made
by an experienced pediatrician in all patients when
they were 3 months old and again at 6 months of age.
Developmental assessment was performed by the
same pediatrician using the Denver Developmental
Screening Test (DDST) Turkish Modification (10). All
patients were referred to our institution’s
otorhinolarnygology clinic for hearing examinations.
Data were analyzed statistically with SPSS v.11.5
for Windows. The Mann-Whitney U test and
Spearman’s correlation test were used for comparison
of nonparametric values, and Fisher’s exact test was
used for dichotomous variables. Results were
calculated as mean ± standard deviation (SD). P
values < 0.05 were regarded as statistically significant.
Results
The study included 13 patients (9 female, 4 male).
Mean age of patients at admission was 5.8 ± 2.4 days
(range: 3-13 days). Mean gestational age was 38.5 ±
1.1 weeks (range: 37-40 weeks) and mean birth weight
was 2828 g ± 413 g (range: 2060-3400 g). Mean
unconjugated bilirubin level at admission was 40.2 ±
−1
−1
6.7 mg dL (range: 30-52 mg dL ).
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Of the 13 patients, 5 met the criteria for phase I
ABE and 8 met the criteria for phase II (Table).
Abnormal MRI findings were observed in 5 patients
(38.4%), 4 of which had a hyperintense signal in the
cerebral white matter and 1 with hyperintensity in the
globus pallidus.
Gross motor delay was present in 11 for the 13
infants (85%) at age 3 months and in 9 of the 13
infants (69%) at age 6 months. DDST scores for all
parameters improved with age. Neurological
examination findings in the patients were as follows:
5 (38%) of the patients had phase I ABE and 8 (62%)
of the patients had phase II. Four of the 5 patients
(patients 2, 3, 10, and 12) with abnormal MRI findings
had moderate (phase II) encephalopathy at admission.
Only 1 patient (no: 9) had initial phase (phase I)
encephalopathy. There was not a statistically
significant correlation between MRI changes and
clinical findings. Demographic characteristics, MRI,
and DDST results are shown in the Table.
ABE phase was significantly correlated with motor
retardation (P = 0.035, r = 0.59) and language
development (P = 0.042; r = 0.57) at age 3 months, but
there were no correlations between ABE phase and
DDST score at age 6 months. Four infants were well
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developed at 6 months of age. Nine infants showed
various developmental handicaps based on DDST
scores at 6 months of age.
Of the 4 healthy infants, 2 had phase I ABE and 2
had phase II ABE. Of the 9 handicapped infants, 3 had
phase I ABE and 6 had phase II ABE. ABE phase was
not statistically significant (P = 0.51). Mean total
bilirubin levels in healthy infants was lower than in
handicapped infants (P = 0.02). Only social
development at 6 months of age was correlated with
opisthotonus (P = 0.034; r = 0.59), hypertonia (P =
0.011; r = 0.68), and high pitched crying (P = 0.034; r
= 0.59). Other developmental abnormalities were not
correlated with clinical findings at admission.
Additionally, there was not a correlation between ABE
phase and abnormal MRI findings (P = 0.32; r = 0.3).
Discussion
There is no doubt about the relationship between
elevated total serum bilirubin (TSB) levels and brain
damage, or that the ability of a single peak bilirubin
level to predict long-term neurodevelopmental
outcome is poor. Sick and preterm infants are more
likely to be vulnerable to the deleterious neurotoxic

Table. Demographic characteristics, total bilirubin, and MRI and DDST results in the study infants.

No.

Sex

Age
(day)

Gestational
age

Weight
(g)

Maximum TSB
−1
(mg dL )

Encephalopathy
stage

MRI findings

1
2
3
4
5
6
7
8
9
10
11
12
13

F
F
M
F
M
F
M
F
F
F
F
M
F

4
6
6
6
5
6
4
5
7
5
13
3
5

40
38
39
39
38
40
37
38
39
37
40
38
37

3100
3300
2060
3000
2700
3100
2500
3000
3200
2500
3400
2600
2300

35
36
30
34
39
39
33
50
40
43
52
46
45

1
2
2
1
1
2
1
2
1
2
2
2
2

Normal
↑T2 in WM
↑T2 in WM
Normal
Normal
Normal
Normal
Normal
↑T1 in WM
↑T1 in WM
Normal
↑T2 in GP
Normal

DDST at 3 DDST at 6
months
months
Abn
N
Abn
N
Abn
Abn
\Abn
Abn
Abn
Abn
Abn
Abn
Abn

N
N
N
N
Abn
Abn
Abn
Abn
Abn
Abn
Abn
Abn
Abn

DDST: Denver Developmental Screening Test; F: female; M: male; TSB: total serum bilirubin; WM: white matter; ↑T1: T1-weighted
hyperintense lesion; ↑T2: T2-weighted hyperintense lesion; GP: globus pallidus. Abn: abnormal, N: normal.
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effects of high bilirubin concentrations. Some
investigators have described clinical and pathologic
kernicterus in premature infants that did not have
hemolytic disease and whose TSB levels were below
20 mg dL−1. Oh et al. concluded that peak TSB
concentrations during the first 2 weeks of life are
directly correlated with death, or neurodevelopmental
impairment, hearing impairment, and Psychomotor
Developmental Index score (11).
Brain MRI studies of infants with kernicterus are
inadequate and results are inconsistent. In most of
these studies only a few patients have been reported
retrospectively. Coskun et al. reported that symmetric
involvement of the globus pallidus, seen as
hyperintense on T1-weighted MRI, is a characteristic
finding of acute kernicterus (7). A bilateral symmetric
high signal in the globus pallidus on T2-weighted
images is the most common reported finding in ABE
(8). Symmetric signal intensity changes in the
subthalamic nucleus, in addition to the globus
pallidus, in T2-weighted images have also been
reported (12). Yokochi reported that high intensity
areas in the globus pallidus were demonstrated
bilaterally with T2-weighted imaging in 3 children
with severe ABE (13). According to Paksoy et al.’s
study, signal changes with T2-weighted MRI, not only
in the globus pallidus, thalamus, and subthalamic
nucleus, but also in the hippocampus, may be seen in
patients with kernicterus (14). To the best of our
knowledge the present study is the first to investigate
if MRI findings predict neurodevelopmental outcome
of newborns with ABE. Only 5 of the 13 patients with
ABE had pathological MRI findings in the present
study. Two of them had white matter hyperintensity
on T2-weighted MRI, 2 of them had white matter
hyperintensity on T1-weighted MRI, and 1 had globus
pallidus hyperintensity on T2-weighted MRI. Only 2
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of the 5 patients had normal neurological
development at 6 months of age. On the other hand,
4 of the remaining 8 patients had moderate to severe
neurological sequelae, although they did not have
abnormal MRI findings.
We also investigated the relationship between
DDST score and ABE. The DDST is a 105-item
developmental screening instrument with 4 subscales
of behavior: social, adaptive, language, and motor
behavior. These scales are scored as definitively
normal, possibly abnormal, and definitively
abnormal. It is known that DDST has low sensitivity
and high specificity for neurodevelopmental
screening (15,16). The sensitivity may be improved by
physicians experienced with DDST. In the present
study we used the DDST Turkish Modification and it
showed some improvement in the patients at 6
months of age, as compared to 3 months (10). The
improvement in the DDST parameters can be
attributed to 2 factors: increased sensitivity of DDST
with age, and clinical improvement in ABE. Some
other tests have been used for evaluating
neurodevelopmental outcome in kernicterus. The
Psychomotor Developmental Index and Mental
Developmental Index have been used to identify the
association between peak serum bilirubin and
neurodevelopmental outcome in extremely low birth
weight infants (11); however, Newman et al. did not
observe any serious neurodevelopmental sequelae in
infants with very high TSB levels (≥ 30 mg dL−1) (17).
In conclusion, the present study shows that MRI
did not predict neurodevelopmental outcome in
newborns with ABE. DDST, an easy and inexpensive
method, may be used for neurodevelopmental
evaluation in these patients at 6 months of age, but
not at 3 months.
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